
George W. Kosturko
Examiner (ID: 15764, Phone: (571)270-5903 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1628, 1621 |
| Total Applications | 821 |
| Issued Applications | 383 |
| Pending Applications | 110 |
| Abandoned Applications | 359 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20192171
[patent_doc_number] => 20250268881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN
[patent_app_type] => utility
[patent_app_number] => 19/207781
[patent_app_country] => US
[patent_app_date] => 2025-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12104
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19207781
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/207781 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | May 13, 2025 | Pending |
Array
(
[id] => 20192171
[patent_doc_number] => 20250268881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN
[patent_app_type] => utility
[patent_app_number] => 19/207781
[patent_app_country] => US
[patent_app_date] => 2025-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12104
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19207781
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/207781 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | May 13, 2025 | Pending |
Array
(
[id] => 19798889
[patent_doc_number] => 20250064814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => FORMULATION PRODUCTION PROCESS
[patent_app_type] => utility
[patent_app_number] => 18/946234
[patent_app_country] => US
[patent_app_date] => 2024-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18946234
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/946234 | Formulation production process | Nov 12, 2024 | Issued |
Array
(
[id] => 19798889
[patent_doc_number] => 20250064814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => FORMULATION PRODUCTION PROCESS
[patent_app_type] => utility
[patent_app_number] => 18/946234
[patent_app_country] => US
[patent_app_date] => 2024-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18946234
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/946234 | Formulation production process | Nov 12, 2024 | Issued |
Array
(
[id] => 19798900
[patent_doc_number] => 20250064825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE
[patent_app_type] => utility
[patent_app_number] => 18/943124
[patent_app_country] => US
[patent_app_date] => 2024-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8007
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943124
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/943124 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | Nov 10, 2024 | Abandoned |
Array
(
[id] => 19798901
[patent_doc_number] => 20250064826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE
[patent_app_type] => utility
[patent_app_number] => 18/943165
[patent_app_country] => US
[patent_app_date] => 2024-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8004
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943165
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/943165 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | Nov 10, 2024 | Pending |
Array
(
[id] => 19815033
[patent_doc_number] => 20250073240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => NEW TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/825447
[patent_app_country] => US
[patent_app_date] => 2024-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18825447
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/825447 | NEW TREATMENT | Sep 4, 2024 | Pending |
Array
(
[id] => 19815033
[patent_doc_number] => 20250073240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => NEW TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/825447
[patent_app_country] => US
[patent_app_date] => 2024-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18825447
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/825447 | NEW TREATMENT | Sep 4, 2024 | Pending |
Array
(
[id] => 19541641
[patent_doc_number] => 20240358677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER
[patent_app_type] => utility
[patent_app_number] => 18/764277
[patent_app_country] => US
[patent_app_date] => 2024-07-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11743
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764277
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/764277 | Lasofoxifene treatment of aromatase-resistant ER | Jul 3, 2024 | Issued |
Array
(
[id] => 19510434
[patent_doc_number] => 20240342120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => MULTIPLE MYELOMA TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/754044
[patent_app_country] => US
[patent_app_date] => 2024-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1898
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754044
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/754044 | MULTIPLE MYELOMA TREATMENT | Jun 24, 2024 | Pending |
Array
(
[id] => 19510442
[patent_doc_number] => 20240342128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => IMMUNE MEMORY INDUCTION BY PLATINUM BASED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/751933
[patent_app_country] => US
[patent_app_date] => 2024-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751933
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/751933 | IMMUNE MEMORY INDUCTION BY PLATINUM BASED COMPOUNDS | Jun 23, 2024 | Pending |
Array
(
[id] => 19845181
[patent_doc_number] => 20250090532
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-20
[patent_title] => SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/655511
[patent_app_country] => US
[patent_app_date] => 2024-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/655511 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | May 5, 2024 | Abandoned |
Array
(
[id] => 20356163
[patent_doc_number] => 12472142
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-18
[patent_title] => Liquid depot for non-invasive sustained delivery of agents to the eye
[patent_app_type] => utility
[patent_app_number] => 18/650914
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 17
[patent_no_of_words] => 9813
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650914
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650914 | Liquid depot for non-invasive sustained delivery of agents to the eye | Apr 29, 2024 | Issued |
Array
(
[id] => 19860639
[patent_doc_number] => 20250099425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 18/643207
[patent_app_country] => US
[patent_app_date] => 2024-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55379
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/643207 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | Apr 22, 2024 | Pending |
Array
(
[id] => 19860639
[patent_doc_number] => 20250099425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 18/643207
[patent_app_country] => US
[patent_app_date] => 2024-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55379
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/643207 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | Apr 22, 2024 | Pending |
Array
(
[id] => 19359259
[patent_doc_number] => 20240261293
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/638097
[patent_app_country] => US
[patent_app_date] => 2024-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638097
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/638097 | COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF | Apr 16, 2024 | Pending |
Array
(
[id] => 19658451
[patent_doc_number] => 20240425516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/636653
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18636653
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/636653 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | Apr 15, 2024 | Abandoned |
Array
(
[id] => 19387843
[patent_doc_number] => 20240277713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations
[patent_app_type] => utility
[patent_app_number] => 18/618767
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21796
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618767
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | Mar 26, 2024 | Pending |
Array
(
[id] => 19316771
[patent_doc_number] => 20240238311
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL
[patent_app_type] => utility
[patent_app_number] => 18/611251
[patent_app_country] => US
[patent_app_date] => 2024-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47587
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611251
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/611251 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | Mar 19, 2024 | Pending |
Array
(
[id] => 19332563
[patent_doc_number] => 20240246993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => CDK Inhibitors And Their Use As Pharmaceuticals
[patent_app_type] => utility
[patent_app_number] => 18/600852
[patent_app_country] => US
[patent_app_date] => 2024-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31008
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 559
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600852
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/600852 | CDK Inhibitors And Their Use As Pharmaceuticals | Mar 10, 2024 | Abandoned |